Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Eli Lilly ( LLY -0.24%) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding financial results, the company has become the largest healthcare player ...

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...